Sionna Therapeutics is trading 5.20% higher at $6.58 after a volatile rebound following the August 10 Phase 2a failure.
- SION-719 produced a -1.0 mmol/L placebo-adjusted sweat-chloride change, and the company would not advance it as an add-on to standard care.
- No new company announcement was identified on August 13; the Nasdaq Composite gained 0.68%, supporting broader risk appetite.
- Shares previously fell 91.18% after the failed trial.